A new NIH trial is suggesting the use of the antiviral drug Remdesivir by Gilead Sciences is improving clinical outcomes. The study published in the New England Journal of Medicine shows that drugs are shortening the recovery period of COVID-19 in patients. The trial involved a total of 1,063 patients who either received the drug intravenously or through a placebo. It was seen the recovery period was fast in patients who received the drug than the placebo population by four days. After obtaining an “emergency use authorization” last month from the FDA, the drug was widely used in critically ill patients to save their lives.
The recovery implies that the patients will be in a condition that they can be discharged from hospitals. The study also showed the drug was beneficial in patients with severe complications of the disease. We see that Hydroxychloroquine trials coming to a halt due to safety concerns. We do not see such upcoming with this drug. Moreover, the drug has positive reviews from the day that we currently have. Therefore, we can see that antiviral drugs can form a major part of the treatment regime in the days.
However, the study also mentions that there was higher mortality in spite of the treatment. Therefore, the study calls for improving the strategies for the treatment using the drug. The report also concluded that the drug alone isn’t sufficient to treat the disease. This will lead us to new studies in the coming days with the drug that will eventually lead us in combating the disease better.
Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!
Source: Fox News